GlassScriptPhysician profile
Juma A Bharadia
NPI 1285651166
$10,264.68
in general payments reported to CMS, 2019-2025
63 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $692 · 2021: $1,748 · 2022: $1,440 · 2023: $1,891 · 2024: $1,651 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.11 | 2021-2025 | Botox, Vraylar, Ubrelvy |
| Ucb, INC. | $954.98 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $776.03 | 2019-2025 | Nuplazid, Daybue |
| Merck Sharp & Dohme LLC | $561.68 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $508.07 | 2020-2025 | Lifevest |
| Mdd US Operations, LLC | $429.03 | 2020-2025 | Gocovri, Gocovri |
| Sk Life Science, INC. | $394.88 | 2021-2025 | |
| Lilly USA, LLC | $353.90 | 2019-2024 | Amyvid, Emgality |
| Emd Serono, INC. | $320.48 | 2020-2025 | |
| Lundbeck LLC | $318.81 | 2021-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $317.92 | 2019-2024 | |
| Amgen INC. | $284.95 | 2019-2023 | Repatha |
| Ipsen Biopharmaceuticals, INC | $258.41 | 2019-2025 | Dysport |
| Janssen Pharmaceuticals, INC | $242.33 | 2019-2024 | Xarelto |
| Pfizer INC. | $235.87 | 2021-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juma Bharadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.